-
Binding Is the Easy Part(Post)
An antibody–drug conjugate is not a targeted drug. It is a delivery problem with an antibody bolted to the front of it. Binding is the easy part, and it is almost never the part that fails. What deci
Belantamab: A Game-Changer in Multiple Myeloma Therapy(Post)Quick Facts About BelantamabWhat is Belantamab?Belantamab Mafodotin is a cutting-edge antibody-drug conjugate (ADC) designed for the treatment of relapsed or refractory multiple myeloma.
One Integrin Chain, Two Partners, Brain or Gut(Post)A chemokine gradient does not move a leukocyte anywhere. It only tells one that has already stopped which way to go. That sentence is the whole map. Trafficking is a four-step cascade and the steps a
Department of Oncology Retreat 2025(Post)Department of Oncology RetreatAssay Genie was honoured to sponsor and participate in the inaugural 2025 Department of Oncology Retreat, hosted by the University of Lausanne and Lausanne
No Ligand, No Kinase, No Problem(Post)HER2 has no ligand. HER3 has no kinase. Together they are the most potent signalling pair in human biology. That single sentence explains most of what is strange about this receptor family and all of
Unconventional T Cells: Already Armed, and No MHC Required(Post)Most immunology is written as though a T cell must first be told what to look for. Three lineages did not read that memo. γδ T cells, invariant NKT cells and MAIT cells leave the thymus with their ef
TGF-Beta SMAD Signalling Pathway: Function, Readouts and Assays(Post)Almost all of the TGF-β in a tissue is already there, and almost none of it is active. That single fact reorganises how the pathway should be studied. Unlike most cytokines, TGF-β is deposited into t
Fc Receptors Explained: ADCC, ADCP, CDC and the CD32B Brake(Post)An antibody's variable domains decide what it binds. Its Fc decides what happens next — and that is not a detail of formulation, it is half the mechanism. Which Fcγ receptor the constant region engag
Chemokine Receptors and Leukocyte Trafficking(Page) Infectious Disease ELISA(Page)Infectious Disease ELISA Kits | Viral, Bacterial & Fungal
Growth Factors Can Cooperate to Promote Tumorigenesis(Post)Introduction Tumorigenesis, the process by which normal cells transform into cancer cells, is a multifaceted and complex event influenced by various internal and external factors. Among the
Immunopeptidomics: Mapping the Hidden Landscape of the Cancer Immunome(Post)Imagine a high-stakes game of hide-and-seek where the seeker is your immune system and the hider is a master of disguise: cancer. For decades, we believed the 'wanted' posters for tumor cells were li
DNA Assembly Cloning(Page) Control Samples Required for ELISA Protocol(Post)Enzyme-Linked Immunosorbent Assay (ELISA) is a powerful analytical biochemistry assay that utilizes antibodies and color change to identify a substance. It is widely used in the field of immunolog
T-Cell Engagers: Signal 1 Without Signal 2(Post)A T-cell engager does not give the T cell an instruction. It gives it an address. A bispecific antibody with one arm on CD3 and the other on a tumour antigen forces two membranes into contact and let
The EGFR/HER Family: Dimerisation, Ligand Independence & Resistance(Page) NLRP3 Inflammasome and Pyroptosis: Pathway, Function and Assays(Post)The inflammasome is one of the few innate pathways that destroys the cell it activates. A macrophage that assembles NLRP3 has committed to a decision it cannot reverse: a priming signal through TLR4
TLR Innate Sensing Pathway: Receptors, MyD88/TRIF and Assays(Post)Toll-like receptors are the reason a milligram of endotoxin can kill a mouse. They are the fastest, least discriminating layer of immunity: germline-encoded sensors that read conserved microbial chem
Questions About Dilutions? A Real Example of How to Prepare Your ELISA Solutions(Post)Quick answer A researcher preparing a Human IL-18 ELISA wasn't sure whether the protocol's “300-fold” HRP-Streptavidin step meant adding 40 µL of concentrat
Regulatory T Cells and the IL-2 Paradox(Page) The Interferonopathies and the Self-DNA Problem(Page) A New Dawn in Lupus Treatment: The Promise of Topical RNA Therapeutics(Post)A New Dawn in Lupus Treatment: The Promise of Topical RNA Therapeutics Systemic Lupus Erythematosus (SLE) is a debilitating autoimmune disease that has long puzzled researchers and clinicians. Howeve
Do Not Eat Me Is Not a Switch(Post)Phagocytosis is a subtraction, not a switch. A macrophage engulfs when its activating signals exceed its inhibitory ones, and every awkward result in the myeloid checkpoint field falls out of that on
Hijacking the Skull's Gateways: A New 'Backdoor' for Brain Drug Delivery(Post)For decades, the brain has been considered an immune sanctuary, protected by the formidable blood-brain barrier. This intricate defense system, while vital for safeguarding our most complex organ, ha
Exhibition at the University of Oxford's BioEscalator(Post)Showcasing Innovation Assay Genie recently took part in an engaging event at Oxford’s BioEscalator, a leading innovation hub supporting scientific progress and entrepreneurship. The day
Tocilizumab: Advancing Therapeutics and Research with Biosimilars(Post)What You Need to Know About TocilizumabWhat is Tocilizumab?Tocilizumab is a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, widely used for managing autoimmune and in
Tiragolumab: Unlocking New Horizons in Cancer Immunotherapy(Post)Quick Facts About TiragolumabWhat is Tiragolumab?Tiragolumab is an anti-TIGIT monoclonal antibody developed to enhance immune responses against cancer cells. It is currently under invest
Unlocking the Next Wave of Cancer Treatment: The Rise of CAR-T Cell Therapy(Post)A New Era in Oncology Chimeric Antigen Receptor (CAR)-T cell therapy represents a paradigm shift in the fight against cancer, offering a personalized and powerful immunotherapy that trains a patient
LPS ELISA Troubleshooting: The Importance of Sample Nature(Post)Quick answer A researcher measuring circulating lipopolysaccharide (LPS) in human serum with our LPS ELISA saw almost no color, even after 30 minutes with substrate. Samples had been test
The Next Leap in Cancer Treatment: CAR-T Cell Therapy's Journey to Mainstream Medicine(Post)For decades, the fight against cancer has been a grueling battle of attrition, with treatments often as harsh as the disease itself. But a revolutionary approach, chimeric antigen receptor (CAR)-T cel
Denosumab: A Comprehensive Overview of Mechanism, Applications, and Research Advances(Post)Biologics · Bone MetabolismDenosumab: RANKL Inhibition, Clinical Applications and BiosimilarsDenosumab is a fully human monoclonal antibody against RANKL, the cytokine that drives osteoclast formation
CD4 T-Helper Differentiation: Th1, Th2, Th17, Treg and Tfh(Post)The antigen tells a CD4 T cell to respond; the cytokine tells it what kind of response to make. A naive CD4⁺ T cell leaving the thymus is uncommitted. Within about seventy-two hours of engaging TCR/C
NK Cell Cytotoxicity Pathway: Receptors, Signalling and Assays(Post)A natural killer cell decides by subtraction. It carries no rearranged antigen receptor and no memory of what it has seen. It presses a panel of germline-encoded receptors against a target and integr
The Interferon Axis: Type I vs Type II Signalling Explained(Post)Both interferon families run through STAT1, and that single shared subunit is why they are so often conflated — and why conflating them is a mistake. Type I interferon assembles STAT1 into a three-pa
Tumour Angiogenesis and the VEGF Axis(Page) Antibody-Drug Conjugates: Internalisation, Trafficking & the Bystander Effect(Page) Dilución de anticuerpos: protocolo, cálculos y control de calidad(Post)Dilución de anticuerpos: protocolo, cálculos y control de calidad Empiece con una serie de diluciones (por ejemplo, 1:10 seguida de una serie 1:2) y siempre incluya controles positivos y negativos pa
Melanoma: Understanding, Diagnosing, and Treating Skin Cancer(Post)Melanoma is an aggressive type of skin cancer that originates in melanocytes, the cells responsible for producing melanin, which gives skin its color. Although it is less common than othe
Extracellular Vesicles in Neurodegenerative Disease: From Pathology to Therapeutic Potential(Post)In the intricate landscape of the brain, cells constantly communicate, sending and receiving messages that govern our thoughts, memories, and movements. For decades, scientists believed this communica
Zolbetuximab: A Breakthrough in Targeting Claudin 18.2 for Cancer Treatment(Post)Quick Facts About ZolbetuximabWhat is Zolbetuximab?Zolbetuximab is a monoclonal antibody that targets Claudin 18.2, a protein overexpressed in gastric and pancreatic cancers, enhancing t
Imalumab: Unveiling Its Mechanism, Clinical Potential, and Biosimilar Advancements(Post)What You Need to Know About ImalumabWhat is Imalumab?Imalumab is a monoclonal antibody targeting macrophage migration inhibitory factor (MIF), a key regulator of inflammation and immune
Assay Genie Sustainability Policy(Page) Western Blot Protocol & Troubleshooting Guide(Page)Western Blot Protocol & Troubleshooting Guide | 14 Steps + 101 Tips | Assay Genie
Unlocking the Next Wave of Cancer Treatment: The Promise and Progress of CAR-T Cell Therapy(Post)Imagine a living drug, engineered from a patient's own immune system, that can hunt down and destroy cancer cells with remarkable precision. This isn't science fiction; it's the reality of Chimeric An
In Vivo CAR-T Engineering: The Dawn of Off-the-Shelf Immunotherapy(Post)Imagine a future where cancer treatment isn't a grueling, months-long process involving cell extraction and reinfusion, but a simple, targeted injection that reprograms your body's own immune cells t
Tezepelumab: A Breakthrough in Severe Asthma Treatment and Research(Post)Quick Facts About TezepelumabWhat is Tezepelumab?Tezepelumab is a monoclonal antibody designed to inhibit thymic stromal lymphopoietin (TSLP), a key driver of airway inflammation in seve
Alsevalimab: Targeting CD47 for Cancer Research and Treatment(Post)Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab
Spatial Transcriptomics: Mapping the Future of Medicine at Cellular Resolution(Post)Spatial Transcriptomics: Mapping the Future of Medicine at Cellular Resolution Imagine being able to create a detailed map of a city, not just showing the streets and buildings, but also revealing th
Bone Resorption Explained: Process, Markers, and Clinical Insights(Post)Bone Biology · BiomarkersBone Resorption: Process, Markers & Clinical SignificanceBone resorption is the process by which osteoclasts break down bone tissue and release its stored minerals into the bl
Non-Small Cell Lung Carcinoma: Understanding, Diagnosing, and Treating NSCLC(Post)Non-Small Cell Lung Carcinoma (NSCLC) is the most common type of lung cancer, representing about 85% of all lung cancer cases. NSCLC includes several subtypes, with distinct biological ch
Lacnotuzumab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About LacnotuzumabWhat is Lacnotuzumab?Lacnotuzumab is a monoclonal antibody targeting CD47, a protein that helps cancer cells evade immune system destruction.What is the mec
T-Cell Co-Stimulation and Agonist Checkpoint Signalling Explained(Post)Signal 1 tells a T cell what it is looking at; signal 2 tells it whether to care. The same peptide–MHC engagement that launches a productive effector response can just as easily install an anergy pro
Programmable Synthetic Hybrid Receptors (Hybrid-Rs): The Next Generation of Precision Immunotherapy(Post)Imagine a world where cancer treatment is no longer a blunt instrument but a precision-guided surgical strike, executed by the body's own immune system. For years, we have dreamed of 'smart' cells th
Basiliximab: Mechanism, Clinical Applications, and Research Advancements(Post)Quick Facts About BasiliximabWhat is Basiliximab?Basiliximab is a monoclonal antibody targeting the CD25 subunit of the IL-2 receptor, primarily used to prevent organ transplant rejectio
Patritumab Deruxtecan: Mechanism, Clinical Applications, and Biosimilar Advances(Post)Quick Facts About Patritumab DeruxtecanWhat is Patritumab Deruxtecan?Patritumab Deruxtecan (HER3-DXd) is an investigational antibody-drug conjugate (ADC) targeting HER3, a receptor impli
Microglia and Neuroinflammation(Page) The Battle of Antibiotics: Penicillin vs. Streptomycin(Post)Microbiology · AntibioticsPenicillin vs Streptomycin: The Battle of AntibioticsPenicillin and streptomycin are two of the most important antibiotics ever discovered — and they work in completely diffe
ELISA High Background Troubleshooting: FBS Matrix Interference(Post)Quick answer A researcher running a Rat Eotaxin/CCL11 (Eotaxin) sandwich ELISA saw sample readings sit above the top standard and wells turn colour the instant TMB was added — even aft
Urea Assays(Page)Urea Assay Kits | Urea Cycle, Ammonia & Amino Acid Assays | Assay Genie
DNA Origami in the Brain: How Nanoscale Structural Folding Governs Neural Development(Post)Imagine a world where we can fold the very fabric of life into microscopic machines, guiding the growth of a single neuron with the precision of a master architect. This isn't science fiction; it is
mRNA-1010 and Beyond: How Moderna's mRNA Platform is Revolutionizing Hantavirus Vaccine Development(Post)Hantavirus, a silent threat lurking in rodent populations, has long posed a significant public health challenge with its severe and often fatal outcomes. For decades, the quest for effective vaccines
Mogamulizumab: Understanding Its Mechanism, Clinical Applications, and the Role of Biosimilars in Research(Post)Quick Info Section: Key Facts About MogamulizumabWhat is Mogamulizumab?Mogamulizumab is an anti-CCR4 monoclonal antibody used primarily for treating certain cancers, including cutaneous
Adaptive immune system molecules(Page) Fc Receptors & Antibody Effector Function(Page) Eosinophils, IL-5 and the Type 2 Granulocyte Axis(Page) Interferon Axis — Type I & Type II Signalling(Page) Citrullination, NETs and Rheumatoid Arthritis(Page)